C
VERV

Covestor’s Verve Therapeutics VERV Stock Holding History

Covestor’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14
Closed – – 2813
2025
Q2 		$0 Hold
14
– – ﹤0.01% 2793
2025
Q1 		$0 Hold
14
– – ﹤0.01% 2765
2024
Q4 		$0 Buy
14
+1
+8% +$6 ﹤0.01% 2778
2024
Q3 		$0 Sell
13
-1
-7% -$6 ﹤0.01% 2813
2024
Q2 		$0 Buy
14
+8
+133% +$50 ﹤0.01% 2797
2024
Q1 		$0 Hold
6
– – ﹤0.01% 2786
2023
Q4 		$0 Sell
6
-1
-14% -$12 ﹤0.01% 2762
2023
Q3 		$0 Sell
7
-1
-13% -$16 ﹤0.01% 2756
2023
Q2 		$0 Buy
8
+3
+60% +$50 ﹤0.01% 2693
2023
Q1 		$0 Hold
5
– – ﹤0.01% 2626
2022
Q4 		$0 Hold
5
– – ﹤0.01% 2646
2022
Q3 		$0 Sell
5
-6
-55% -$191 ﹤0.01% 2656
2022
Q2 		$0 Buy
11
+2
+22% +$31 ﹤0.01% 2401
2022
Q1 		$0 Sell
9
-2
-18% -$57 ﹤0.01% 2464
2021
Q4 		$0 Buy
+11
New +$462 ﹤0.01% 2315

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Covestor's VERV Position: Q3 2025 in Review

Covestor sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 14 shares.

Covestor first reported a position in VERV in Q4 2021 and held it in 15 quarters. The position peaked at $0 in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Covestor reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Covestor sold 14 Verve Therapeutics shares in Q3 2025.
  • Covestor first reported a position in Verve Therapeutics in Q4 2021 and held it in 15 quarters.
  • Covestor's Verve Therapeutics position peaked at $0 in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Covestor's 13F filing for Q3 2025, filed 30 Oct 2025.